Ocrelizumab for Relapsing Multiple Sclerosis

"Due to its approval status, Ocrelizumab's safety is rated a 3 on our evaluation scale. This rating indicates that the drug has completed Phase 4 of clinical trials."

"Clinicaltrials.gov states that this research trial is currently not enrolling any new participants; it was uploaded on July 30th 2020 and edited september 12th 2022, but there are 578 other trials in progress at the moment."

"This clinical trial is looking to enrol 150 individuals suffering from multiple sclerosis, between the ages of 18 and 65. Additionally, eligible candidates must self-identify as Black or African American or Hispanic/Latino American; have a diagnosis of RMS with an EDSS score no higher than 5.5 at enrollment; be new to treatment (or switching away from certain disease modifying therapies); and remain neurologically stable for 30 days before randomization and baseline assessments. Moreover, female participants must agree to avoid sexual intercourse or utilize accepted contraceptive methods during the study period plus 6 months following their final dose of ocrelizumab if they"

"As indicated by the requirements for inclusion, study participants must fall within an age range of 18 to 65 years. Alternatively, there are 45 studies that target minors and a further 402 trials designed specifically for people over the age of 65."

"Ocrelizumab was first tested in 2008 under the sponsorship of Genentech, Inc. which included 220 participants. This initial trial resulted in Phase 2 approval for Ocrelizumab and today there are 29 live studies taking place over 321 cities and 60 countries worldwide."

"Ocrelizumab was first studied in 2008 at CHU De Nimes, Hopital Caremeau; Service De Neurologie Du Prof. Pierre Labauge and has since been a subject of 10 completed clinical trials. Presently, 29 distinct studies are actively enrolment patients with numerous locations situated within the Dallas area of Texas."

"This clinical trial has 34 recruitment sites, such as the MS Treatment Center of Dallas in Dallas, Guilford Neurologic Associates in Greensboro, and Center for Neurology and Spine - Phoenix - Hunt - PPDS in Phoenix."

"Regrettably, this particular study is not actively seeking participants at the moment. It was initially registered on July 30th 2020 and further modified as recently as September 12th 2022. If you are interested in engaging with other clinical trials, there are 549 medical studies for multiple sclerosis and 29 investigations utilising Ocrelizumab that currently require patient recruitment."